Table 1 Baseline characteristics of included studies
First author | Year | Patients ( n ) | Age (mean ± std) | Sex(M/F) | Surgery | TEA medication | |||
|---|---|---|---|---|---|---|---|---|---|
|  |  | TEA ± GA | GA | TEA ± GA | GA | TEA ± GA | GA |  |  |
Bach | 2002 | 13 | 13 | 60 ± 8 | 64 ± 7 | 11/2 | 17/10 | ECABG | Bupivacaine |
Bakhtiary | 2007 | 66 | 66 | 66 ± 8 | 64 ± 9 | 54/12 | 58/8 | OCBG | Ropivacaine and sufentanil |
Barrington | 2005 | 60 | 60 | 63 ± 9 | 62 ± 10 | 53/7 | 51/9 | CABG | Ropivacaine/fentanyl |
Berendes | 2003 | 36 | 37 | 61 ± 11 | 59 ± 12 | 11/26 | 9/27 | ECABG | Bupivacaine and sufentanil |
Caputo | 2009 | 36 | 38 | 63.8 ± 9.8 | 66.5 ± 9.3 | 32/4 | 34/4 | OCBG | Propofol and fentanyl |
Caputo | 2011 | 109 | 117 | 65.9 ± 8.8 | 65.5 ± 8.6 | 102/7 | 102/15 | OCBG | Bupivacaine |
de Vries | 2002 | 30 | 60 | 57 ± 11 | 60 ± 11 | 20/10 | 47/13 | OPCABG | Bupivacaine and sufentanil |
Fillinger | 2002 | 30 | 30 | - | - | - | - | CABG | Bupivacaine/ morphine |
Hansdottir | 2006 | 55 | 55 | 65 ± 10 | 68 ± 11 | 38/20 | 38/17 | ECS | Bupivacaine |
Heijmans | 2007 | 15 | 45 | 61 ± 10 | - | - | - | ECS | Bupivacaine and remifentanil |
Kendall | 2004 | 10 | 20 | 66 ± 4.6 | - | 8/2 | 14/6 | ECS | Isoflurane and bupivacaine |
Lagunilla | 2006 | 25 | 25 | 66.08 ± 8.28 | 64.04 ± 10.15 | 22/3 | 22/3 | ECS | Ropivacaine/fentanyl |
Lundstrom | 2005 | 26 | 24 | 66 ± 15 | 63 ± 11 | - | - | ECS | Bupivacaine |
Nygard | 2004 | 79 | 84 | - | - | - | - | CABG | Bupivacaine |
Onan | 2011 | 15 | 15 | 58.5 ± 6.0 | 59.4 ± 9.3 | 14/1 | 13/2 | CABG | Bupivacaine |
Priestley | 2002 | 50 | 50 | 58 ± 10 | 60 ± 8 | 8/42 | 6/44 | CABG | Ropivacaine/fentanyl |
Scott | 2001 | 206 | 202 | 59.2 ± 8.94 | 58.8 ± 9.18 | - | - | CABG | Bupivacaine |
Svircevic | 2011 | 325 | 329 | 65 ± 10 | 64 ± 10 | 266/59 | 277/52 | CABG |  |
Kiliçkan | 2006 | 40 | 40 | 61.1 ± 8.9 | 58.6 ± 13.1 | 16/4 | 17/3 | CABG | Bupivacaine/fentanyl |
Royse | 2003 | 37 | 39 | 64.2 ± 9.3 | 65.1 ± 10.8 | 30/7 | 30/9 | CABG | Ropivacaine/fentanyl |
Sharma | 2010 | 30 | 30 | 58.2 ± 8.0 | 58.0 ± 8.3 | 27/3 | 29/1 | OPCABG | Bupivacaine/fentanyl |
Gurses | 2013 | 32 | 32 | 62.8 ± 10.5 | 61.7 ± 8.8 | 8/24 | 10/22 | CABG | Fentanyl/ levobupivacaine |
Rajakaruna | 2013 | 109 | 117 | 65.9 ± 8.8 | 65.5 ± 8.6 | 102/7 | 102/15 | OPCABG | Bupivacaine |
Jakobsen | 2012 | 30 | 30 | 70.9 ± 4.6 | 71.6 ± 4.5 | 21/9 | 18/12 | ECS | Bupivacaine |
Onan | 2013 | 20 | 20 | 59.2 ± 9.6 | 58.1 ± 6.7 | 19/1 | 17/3 | CABG | Bupivacaine |